KROS
Price
$10.28
Change
+$0.24 (+2.39%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
416.98M
27 days until earnings call
MEOBF
Price
$1.37
Change
-$0.25 (-15.43%)
Updated
Mar 12 closing price
Capitalization
1.5B
54 days until earnings call
Ad is loading...

KROS vs MEOBF

Header iconKROS vs MEOBF Comparison
Open Charts KROS vs MEOBFBanner chart's image
Keros Therapeutics
Price$10.28
Change+$0.24 (+2.39%)
Volume$11.74K
Capitalization416.98M
Mesoblast
Price$1.37
Change-$0.25 (-15.43%)
Volume$135
Capitalization1.5B
KROS vs MEOBF Comparison Chart
Loading...
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KROS vs. MEOBF commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KROS is a Hold and MEOBF is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (KROS: $10.28 vs. MEOBF: $1.37)
Brand notoriety: KROS and MEOBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KROS: 131% vs. MEOBF: 14%
Market capitalization -- KROS: $416.98M vs. MEOBF: $1.5B
KROS [@Biotechnology] is valued at $416.98M. MEOBF’s [@Biotechnology] market capitalization is $1.5B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KROS’s FA Score shows that 0 FA rating(s) are green whileMEOBF’s FA Score has 0 green FA rating(s).

  • KROS’s FA Score: 0 green, 5 red.
  • MEOBF’s FA Score: 0 green, 5 red.
According to our system of comparison, MEOBF is a better buy in the long-term than KROS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KROS’s TA Score shows that 5 TA indicator(s) are bullish.

  • KROS’s TA Score: 5 bullish, 5 bearish.

Price Growth

KROS (@Biotechnology) experienced а -6.46% price change this week, while MEOBF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.91%. For the same industry, the average monthly price growth was -11.19%, and the average quarterly price growth was -14.86%.

Reported Earning Dates

KROS is expected to report earnings on May 01, 2025.

MEOBF is expected to report earnings on May 28, 2025.

Industries' Descriptions

@Biotechnology (-8.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEOBF($1.5B) has a higher market cap than KROS($417M). KROS YTD gains are higher at: -35.060 vs. MEOBF (-37.727). MEOBF has higher annual earnings (EBITDA): -77.78M vs. KROS (-185.82M). KROS has more cash in the bank: 560M vs. MEOBF (37.7M). KROS has less debt than MEOBF: KROS (18.9M) vs MEOBF (126M). MEOBF has higher revenues than KROS: MEOBF (5.67M) vs KROS (3.55M).
KROSMEOBFKROS / MEOBF
Capitalization417M1.5B28%
EBITDA-185.82M-77.78M239%
Gain YTD-35.060-37.72793%
P/E RatioN/AN/A-
Revenue3.55M5.67M63%
Total Cash560M37.7M1,485%
Total Debt18.9M126M15%
FUNDAMENTALS RATINGS
MEOBF: Fundamental Ratings
MEOBF
OUTLOOK RATING
1..100
38
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
50
SEASONALITY SCORE
1..100
46

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
KROS
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 15 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NSBCX60.40N/A
N/A
Nuveen Dividend Growth C
ERSTX25.49N/A
N/A
Eaton Vance Large-Cap Value R
BPSCX23.22N/A
N/A
Boston Partners Small Cap Value II Inv
TRXCX11.38N/A
N/A
Catalyst/MAP Global Balanced C
FDVKX12.17N/A
N/A
Fidelity Value Discovery K6

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INZY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+2.39%
INZY - KROS
43%
Loosely correlated
-5.51%
AXON - KROS
43%
Loosely correlated
-3.35%
RAPT - KROS
39%
Loosely correlated
-3.88%
DNLI - KROS
39%
Loosely correlated
-6.91%
XENE - KROS
39%
Loosely correlated
-2.48%
More

MEOBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEOBF
1D Price
Change %
MEOBF100%
N/A
SPHDF - MEOBF
50%
Loosely correlated
N/A
AVTX - MEOBF
46%
Loosely correlated
-5.51%
COGT - MEOBF
39%
Loosely correlated
-6.73%
MESO - MEOBF
26%
Poorly correlated
-1.78%
KROS - MEOBF
26%
Poorly correlated
+2.39%
More